Peter Welford
Stock Analyst at Jefferies
(2.49)
# 2,251
Out of 4,854 analysts
13
Total ratings
80%
Success rate
8.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Welford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GSK GSK plc | Downgrades: Hold | n/a | $41.20 | - | 3 | Nov 12, 2024 | |
| NVS Novartis AG | Downgrades: Hold | n/a | $118.02 | - | 2 | Sep 3, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $72.88 | - | 4 | Jan 3, 2024 | |
| GLPG Galapagos NV | Upgrades: Hold | $49 → $47 | $27.76 | +70.03% | 3 | Jan 23, 2023 | |
| GMAB Genmab | Downgrades: Hold | n/a | $22.21 | - | 1 | Sep 16, 2021 |
GSK plc
Nov 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $41.20
Upside: -
Novartis AG
Sep 3, 2024
Downgrades: Hold
Price Target: n/a
Current: $118.02
Upside: -
AstraZeneca
Jan 3, 2024
Downgrades: Hold
Price Target: n/a
Current: $72.88
Upside: -
Galapagos NV
Jan 23, 2023
Upgrades: Hold
Price Target: $49 → $47
Current: $27.76
Upside: +70.03%
Genmab
Sep 16, 2021
Downgrades: Hold
Price Target: n/a
Current: $22.21
Upside: -